$ABBV IMBRUVICAÂ Data in CLL Show up to 7 years of PFS in 80 of Previously Untreated Patients the Longest Followup for a BTKi httpswww.prnewswire.comnewsreleasesimbruvicaibrutinibdatainchroniclymphocyticleukemiacllshowuptosevenyears

$ABBV IMBRUVICA® Data in #CLL Show up to 7 years of PFS in 80% of Previously Untreated Patients, the Longest Follow-up for a BTKi https://www.prnewswire.com/news-releases/imbruvica-ibrutinib-data-in-chronic-lymphocytic-leukemia-cll-show-up-to-seven-years

$ABBV IMBRUVICA® Data in #CLL Show up to 7 years of PFS in 80% of Previously Untreated Patients, the Longest Follow-up for a BTKi https://www.prnewswire.com/news-releases/imbruvica-ibrutinib-data-in-chronic-lymphocytic-leukemia-cll-show-up-to-seven-years-of-progression-free-survival-pfs-in-80-percent-of-previously-untreated-patients-the-longest-follow-up-for-a-brutons-tyrosine-kinase-inhib-300758683.html …

More From BioPortfolio on "$ABBV IMBRUVICA® Data in #CLL Show up to 7 years of PFS in 80% of Previously Untreated Patients, the Longest Follow-up for a BTKi https://www.prnewswire.com/news-releases/imbruvica-ibrutinib-data-in-chronic-lymphocytic-leukemia-cll-show-up-to-seven-years"